ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation…
ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. a clinical-stage, natural killer cell-based therapeutics company, announced that the first patient has been…
Read More...
Read More...
